A decade of progress: How have SGLT2i transformed CKM syndrome management?

17 Sep 2025
A decade of progress: How have SGLT2i transformed CKM syndrome management?
Cardiovascular-kidney metabolic (CKM) syndrome affects >90 percent of adults in Hong Kong. MIMS Doctor reviews current recommendations on CKM syndrome management and examines how clinical practice has been transformed with sodium-glucose cotransporter 2 inhibitors (SGLT2i).

Related MIMS Drugs

Resources

A DECADE OF PROGRESS: How have SGLT2i transformed CKM syndrome management?

A DECADE OF PROGRESS: How have SGLT2i transformed CKM syndrome management?

A DECADE OF PROGRESS: How have SGLT2i transformed CKM syndrome management?

A DECADE OF PROGRESS: How have SGLT2i transformed CKM syndrome management?